FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 24, 2026
Neurogene Inc. (NGNE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $90.4 million. Free cash flow was -$78.4 million. As of Jun 30, 2026 it held $225.4 million in cash and investments and $8.3 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-90.35M
-20.2% vs prior year
Operating cash flow (TTM)
$-86.82M
-18.4% vs year-ago TTM
Free cash flow (TTM)
$-87.71M
-17.7% vs year-ago TTM
EPS
$-4.24
+0.9% vs prior year
Dividend per share
None
Shares outstanding
15.57M
+4.3% vs prior year
Net cash
$217.05M
as of Jun 30, 2026
Operating margin
-8930.3%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGNE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404644
- Former names
- Neoleukin Therapeutics, Inc. (until Dec 6, 2023); AQUINOX PHARMACEUTICALS, INC (until Aug 12, 2019); AQUINOX PHARMACEUTICALS (USA) INC (until Dec 24, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $925,000 | — | — | — |
| Operating income | -$103.3M | -$82.6M | -$55.6M | -$56.5M | -$60.7M |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$55.2M | -$60.7M |
| Diluted EPS | -$4.24 | -$4.28 | — | -$1.04 | -$1.10 |
| Operating cash flow | -$77.2M | -$70.6M | -$51.4M | -$52.8M | -$47.6M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$55.1M | -$50.8M |
| Total assets | $288.6M | $335.7M | $222.6M | $109.3M | $163.3M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $10.6M | $20.4M |
| Stockholders' equity | $264.9M | $310.4M | $186.0M | -$145.7M | -$91.9M |
| Cash and investments | $269.0M | $312.4M | $197.2M | $82.0M | $142.5M |
| Total debt | $9.9M | $12.4M | $15.0M | $4.7M | $13.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 8, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
All 750 Neurogene Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.